In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea

Yonsei Medical Journal

Volumn 41, Issue 5, 2000, Pages 563-569

  Hwang, Sang Hyun ^a   Kim, Mi Na ^a,c   Pai, Chik Hyun ^a   Huh, Dong Ho ^b   Shin, Wan Shik ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Enterococci; MRSA; Multi drug resistant; Quinupristin dalfopristin (Q D)

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN; ERYTHROMYCIN; GENTAMICIN; OXACILLIN; QUINUPRISTIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SENSITIVITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; SOUTH KOREA;

EID: 0033777705     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2000.41.5.563     Document Type: Article

References (27)

1. Arthur M, Reynolds PE, Depardieu F, Evers S, Dutka-Malen S, Quintiliani R Jr, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996;32:11-6.
2. Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin-resistant enterocci in New York City. Lancet 1993;342:76-9.
3. Park JW, Kim YR, Shin WS, Kang MW, Han KJ, Shim SI. Susceptibility tests of vancomycin-resistant enterococci. Korean J Infect Dis 1992;24:133-7.
4. Lee WG, Jung MK, Kwak YS. Vancomycin-resistant enterococci: incidence, antimicrobial susceptibility, and resistance genotypes. Korean J Clin Pathol 1998;18:51-6.
5. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
6. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
7. CDC. Staphylococcus aureus with reduced susceptibility to vancomycin-United States. MMWR 1997;46:765-6.
8. Kim MN, Hiramatsu K, Pai CH. Vancomycin resistant Staphylococcus aureus in Korea. Korean J Clin Microbiol 1999;2:S55.
9. Jamjian C, Barrett MS, Jones RN. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30 : 70 ratio) compared to alternative ratios for in vitro testing. Diagn Microbiol Infect Dis 1997;27:129-38.
10. Aumercier M, Bouhallab S, Capmau ML, Le Goffic F. RP59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother 1992;30 Suppl A:9-14.
11. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;31:437-51.
12. Dowzicky M, Nadler HL, Feger C, Talbot G, Bompart F, Pease M. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 1998;104:34S-42S.
13. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989;27:731-4.
14. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-forth edition; approved standard. NCCLS document. M7-A4 Wayne, Pennsylvania: NCCLS; 1997.
15. NCCLS. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. NCCLS document. M100-S9. Wayne, Pennsylvania: NCCLS; 1999.
16. Barry AL, Fuchs PC, Brown SD. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother 1997;39 Suppl A:87-92.
17. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In: Lorian V, editor. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams & Wilkins; 1996. p. 101.
18. Rende-Fournier R, LeClercq R, Galimand M, Duval J, Courvalin P. Identification of the sat A gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM 4145. Antimicrob Agents Chemother 1993;37:2119-25.
19. Mouton JW, Endtz HP, den Hollander JG, van den Braak N, Verbrugh HA. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J Antimicrob Chemother 1997;39 Suppl A:75-80.
20. Caron F, Gold HS, Wennersten CB, Farris MG, Moellering RC Jr, Eliopoulos GM. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancornycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41: 2749-53.
21. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therpy for Enterococcus faecium bacteremia. Clin Infect Dis 1997;24:90-1.
22. Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr. In vitro activity of KP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:598-601.
23. Williams JD, Maskell JP, Whiley AC, Sefton AM. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. J Antimicrob Chemother 1997;39 Suppl A:41-6.
24. FDA. Approval of Synercid for certain vancomycin resistant infections. FDA talk paper. 1999;T99-44.
25. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP59500 on Staphylacoccus aureus including strains with a raised MBC. J Antimicrob Chemother 1994;33: 1219-22.
26. Boswell FJ, Sunderland J, Andrews JM, Wise R. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods. J Antimicrob Chemother 1997;39 Suppl A:29-32.
27. Denny AE, Peterson LR, Gerding DN, Hall WH. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med 1979;139:1026-31.